In May 2017, Volitionrx Ltd (NYSE:VNRX) presented the final data from its 8,000-person clinical validation study of the Nu.Q™ Colorectal Cancer Screening Triage Test. Patients screened with this product would have required 24.5% fewer colonoscopies. The first potential market will be Denmark with feedback expected in about September 2017.
Triage test: Successful 8,000-person clinical trial
VolitionRx presented data from the validation portion of the Nu.Q™ Colorectal Cancer Screening Triage Test clinical trial. This portion of the trial was prospective and examined 4,076 patients with a positive fecal immunochemical test (FIT) result. It found that it could eliminate 22% of these FIT-positive patients from needing a colonoscopy while identifying 95% of colorectal cancer (CRC) cases. When combined with the patients from previous portions, the total result would be a 24.5% reduction in colonoscopies, which is remarkably close to the 25% the test was designed for.
To read the entire report Please click on the pdf File Below